Fulcrum inks discovery deal with Camp4 Therapeutics

With a new CEO at the helm and its hema­to­log­i­cal pro­gram still un­der a clin­i­cal hold, Ful­crum Ther­a­peu­tics has signed a li­cens­ing and dis­cov­ery deal with RNA start­up Camp4 Ther­a­peu­tics to de­vel­op a treat­ment for a rare blood dis­or­der.

Di­a­mond-Black­fan ane­mia is a con­gen­i­tal dis­ease that af­fects around 5,000 peo­ple world­wide, Ful­crum wrote in a press re­lease Mon­day. Pa­tients who have the dis­ease, usu­al­ly di­ag­nosed at birth, can be treat­ed with steroids and blood trans­fu­sions, ac­cord­ing to Boston Chil­dren’s Hos­pi­tal. The on­ly known cure is a stem cell trans­plant.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN